Figure 5.

Murine FSHR SynCon Vaccine Delays Growth of FSHR⁺ Tumors and Promotes Recruitment of T Cells to the Tumor Microenvironment

(A) Schematic of tumor challenge experiments. (B) Survival curve of ID8-Defb29/Vegf-a-Fshr-bearing mice treated with murine FSHR SynCon vaccine or pVAX empty vector (pooled from 3 independent experiments of n = 5–10 mice per group). (C and D) Luciferase quantification (C) and image (D) of ID8-Defb29/Vegf-a-Fshr-bearing mice treated with mouse FSHR vaccine or empty vector on day 42 of tumor progression (representative of 2 independent experiments of n = 5 mice per group). (E) Percentage of T cells of the total CD45⁺ cells in the tumor microenvironment (n = 10, pool of 2 independent experiments). (F) Pie charts representing the proportion of CD4⁺ and CD8⁺ T cells in the tumor microenviroenment of each of the groups. The pie size corresponds to the percentage of total T cells in the tumor microenvironment. (G) Percentage of CD8⁺ T cells of the total T cells in the tumor microenvironment of mice from the different groups (n = 10, pool of 2 independent experiments). (H) Interferon-γ ELISPOT of cells from the tumor microenvironment from mice treated with murine FSHR SynCon vaccine or empty vector pulsed with murine FSHR peptides and ELISPOT representative picture (pool of 3 independent experiments with n = 5–10 mice per group). (I) Tumor volume of mice bearing TRAMPC2-Fshr treated with mouse FSHR vaccine or empty vector (log rank, unpaired t test, and linear regression). Error bars represent SEM. **p < 0.01, ***p < 0.001.